Skip to main content
logo
Atrium Therapeutics, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
11.49
-0.42 (-3.53%)
Jul 24, 2026, 4:00 PM EDT - Market closed

Atrium Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
18.7618.7610.99.569.229.33
Revenue Growth
72.11%72.11%13.98%3.64%-1.09%37.41%
Gross Profit
18.7618.7610.99.569.229.33
Operating Income
-745.94-745.94-378.94-235.6-178.91-118.05
Net Income
-684.63-684.63-322.3-212.22-174-118.01
Earnings Per Share
-4.97-4.97-2.89-2.91-3.34-2.85
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,6971,6971,501595.35610.73405.54
Total Debt
49.2549.256.89.8510.6911.73
Net Cash (Debt)
1,6481,6481,495585.5600.04393.81
Net Cash Growth
10.23%10.23%155.29%-2.42%52.37%20.36%
Net Cash Per Share
11.9611.9613.408.0211.509.51

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-650.44-650.44-300.87-119.06-136.27-94.81
Capital Expenditures
-13.32-13.32-7.07-4.23-2.82-3.74
Free Cash Flow
-663.76-663.76-307.94-123.29-139.09-98.55
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-3977.30%-3977.30%-3477.43%-2464.41%-1939.65%-1265.83%
Pretax Margin
-3650.39%-3650.39%-2957.71%-2219.87%-1886.33%-1265.38%
Profit Margin
-3650.39%-3650.39%-2957.71%-2219.87%-1886.33%-1265.38%
FCF Margin
-3539.11%-3539.11%-2825.88%-1289.67%-1507.92%-1056.76%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
5.36581.52319.9575.05167.84121.71